The efficiency of Cell therapy for Werdnig Hoffman patients
Phase 2
- Conditions
- Werdnig Hoffman.Infantile spinal muscular atrophy, type I [Werdnig-Hoffman]
- Registration Number
- IRCT2015073023417N1
- Lead Sponsor
- Vice chancellor for research, Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Age under 12 month; Weak muscle tone; Weakness in mobility; Patients sitting without full conduction of nerve; Existence of home senses; Normal Brain function;
Exclusion criteria:
Age beyound 12 month; Brain abnormality; Loss of sensory functions; Malignancies.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Muscle Tone. Timepoint: Before intervention, 3 month after final intervention. Method of measurement: Electromyogram (EMG).
- Secondary Outcome Measures
Name Time Method Change in patients muscle tone. Timepoint: Immediately after intervention. Method of measurement: Electromyogram.;Existence of injected cells. Timepoint: After final intervention. Method of measurement: Spinal cord fluid sampling.;Sensitivity or infection. Timepoint: After intervention. Method of measurement: Direct observation.;Patients Longevity. Timepoint: After the final intervention. Method of measurement: Direct observation.